White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration
Abstract
Cognitive tests and nonamyloid imaging biomarkers do not consistently identify preclinical AD. The objective of this study was to evaluate whether white matter hyperintensity (WMH) volume, a cerebrovascular disease marker, is more associated with preclinical AD than conventional AD biomarkers and cognitive tests.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2016
- Source ID
- 10.1016/j.dadm.2016.03.001
Entities
People
- Benjamin M. Kandel
- Brian B Avants
- Christos Davatzikos
- Corey T. Mcmillan
- David A. Wolk
- Guray Erus
- James C. Gee
- Jimit Doshi
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- BioClinica
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Laboratoires Servier
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Norman Cousins Center for Psychoneuroimmunology
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Pennsylvania